Cargando…
The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases
BACKGROUND: There is a lack of fully validated patient-reported outcome measures for progressive fibrosing interstitial lung disease (ILD). We aimed to validate the King's Brief Interstitial Lung Disease (K-BILD) questionnaire for measuring health-related quality of life (HRQoL) in these patien...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160394/ https://www.ncbi.nlm.nih.gov/pubmed/34764181 http://dx.doi.org/10.1183/13993003.01790-2021 |
_version_ | 1784719261419175936 |
---|---|
author | Birring, Surinder S. Bushnell, Donald M. Baldwin, Michael Mueller, Heiko Male, Natalia Rohr, Klaus B. Inoue, Yoshikazu |
author_facet | Birring, Surinder S. Bushnell, Donald M. Baldwin, Michael Mueller, Heiko Male, Natalia Rohr, Klaus B. Inoue, Yoshikazu |
author_sort | Birring, Surinder S. |
collection | PubMed |
description | BACKGROUND: There is a lack of fully validated patient-reported outcome measures for progressive fibrosing interstitial lung disease (ILD). We aimed to validate the King's Brief Interstitial Lung Disease (K-BILD) questionnaire for measuring health-related quality of life (HRQoL) in these patients. We also aimed to estimate the meaningful change threshold for interpreting stabilisation of HRQoL as a clinical end-point in progressive fibrosing ILD, where the current goal of treatment is disease stability and slowing progression. METHODS: This analysis evaluated data from 663 patients with progressive fibrosing ILD other than idiopathic pulmonary fibrosis from the INBUILD trial. Validation of the measurement properties was assessed for internal consistency, test–retest reliability, construct validity, known-groups validity and responsiveness. We calculated meaningful change thresholds for treatment response using anchor-based (within-patient) and distribution-based methods. RESULTS: K-BILD had strong internal consistency (Cronbach's α was 0.94 for total score, 0.88 for breathlessness and activities, 0.91 for psychological, and 0.79 for chest symptoms). The test–retest reliability intraclass correlation coefficient was 0.74 for K-BILD total score. K-BILD demonstrated weak correlations with forced vital capacity (FVC) percent predicted. Known-groups validity showed significant differences in K-BILD scores for patient groups with different disease severity based on use of supplemental oxygen or baseline FVC % pred (≤70% or >70%). We estimated a meaningful change threshold of ≥ –2 units for K-BILD total score for defining patients who remain stable/improved versus those with progressive deterioration. CONCLUSIONS: Our results validate K-BILD as a tool for assessing HRQoL in patients with progressive fibrosing ILD and set a meaningful change threshold of ≥ –2 units for K-BILD total score. |
format | Online Article Text |
id | pubmed-9160394 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-91603942022-06-05 The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases Birring, Surinder S. Bushnell, Donald M. Baldwin, Michael Mueller, Heiko Male, Natalia Rohr, Klaus B. Inoue, Yoshikazu Eur Respir J Original Research Articles BACKGROUND: There is a lack of fully validated patient-reported outcome measures for progressive fibrosing interstitial lung disease (ILD). We aimed to validate the King's Brief Interstitial Lung Disease (K-BILD) questionnaire for measuring health-related quality of life (HRQoL) in these patients. We also aimed to estimate the meaningful change threshold for interpreting stabilisation of HRQoL as a clinical end-point in progressive fibrosing ILD, where the current goal of treatment is disease stability and slowing progression. METHODS: This analysis evaluated data from 663 patients with progressive fibrosing ILD other than idiopathic pulmonary fibrosis from the INBUILD trial. Validation of the measurement properties was assessed for internal consistency, test–retest reliability, construct validity, known-groups validity and responsiveness. We calculated meaningful change thresholds for treatment response using anchor-based (within-patient) and distribution-based methods. RESULTS: K-BILD had strong internal consistency (Cronbach's α was 0.94 for total score, 0.88 for breathlessness and activities, 0.91 for psychological, and 0.79 for chest symptoms). The test–retest reliability intraclass correlation coefficient was 0.74 for K-BILD total score. K-BILD demonstrated weak correlations with forced vital capacity (FVC) percent predicted. Known-groups validity showed significant differences in K-BILD scores for patient groups with different disease severity based on use of supplemental oxygen or baseline FVC % pred (≤70% or >70%). We estimated a meaningful change threshold of ≥ –2 units for K-BILD total score for defining patients who remain stable/improved versus those with progressive deterioration. CONCLUSIONS: Our results validate K-BILD as a tool for assessing HRQoL in patients with progressive fibrosing ILD and set a meaningful change threshold of ≥ –2 units for K-BILD total score. European Respiratory Society 2022-06-02 /pmc/articles/PMC9160394/ /pubmed/34764181 http://dx.doi.org/10.1183/13993003.01790-2021 Text en Copyright ©The authors 2022. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org) |
spellingShingle | Original Research Articles Birring, Surinder S. Bushnell, Donald M. Baldwin, Michael Mueller, Heiko Male, Natalia Rohr, Klaus B. Inoue, Yoshikazu The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases |
title | The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases |
title_full | The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases |
title_fullStr | The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases |
title_full_unstemmed | The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases |
title_short | The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases |
title_sort | psychometric properties of the king's brief interstitial lung disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160394/ https://www.ncbi.nlm.nih.gov/pubmed/34764181 http://dx.doi.org/10.1183/13993003.01790-2021 |
work_keys_str_mv | AT birringsurinders thepsychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases AT bushnelldonaldm thepsychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases AT baldwinmichael thepsychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases AT muellerheiko thepsychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases AT malenatalia thepsychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases AT rohrklausb thepsychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases AT inoueyoshikazu thepsychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases AT birringsurinders psychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases AT bushnelldonaldm psychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases AT baldwinmichael psychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases AT muellerheiko psychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases AT malenatalia psychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases AT rohrklausb psychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases AT inoueyoshikazu psychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases |